

Teva Pharmaceutical Industries Ltd.

Q2 2018

August 2, 2018



Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights;
 - our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
 - our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
 - compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
 - other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;
- and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including the sections thereof captioned "Risk Factors" and "Forward Looking Statements," and in our subsequent quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our press release reporting our 2018 second quarter financial results, as well as our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, for a reconciliation of the GAAP results to the adjusted non-GAAP figures. The non-GAAP data presented by Teva are the results used by Teva's management and board of directors to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management. Teva provides such non-GAAP data to investors as supplemental data and not in substitution or replacement for GAAP measure, because management believes such data provides useful information to investors. A reconciliation of forward-looking non-GAAP estimates to the corresponding GAAP measures is not being provided due to the unreasonable efforts required to prepare it.

Kåre Schultz

Chief Executive Officer



Quarterly highlights

- Q2'18 figures include:
 - Revenues of \$4.7 billion
 - GAAP diluted loss per share of \$0.24 and non-GAAP diluted EPS of \$0.78
 - Free cash flow of \$ 0.6 billion
- Restructuring program on schedule: Significant spend base reduction of over \$1 billion since start of year
- North American generic revenues vs. Q2 2017 impacted by competition to Gx Concerta and price erosion
- AUSTEDO® rapid growth continues
- Copaxone® maintained share in the U.S.
- Solid performance in Europe fueled by new product launches
- Net debt decreased by ~\$1 billion to \$28.4 billion

Raising 2018 guidance


Non-GAAP EPS from \$2.40-2.65 to \$2.55-2.80

Free Cash flow from \$3.0–3.2 billion to \$3.2-3.4 billion


Copaxone® Maintaining Share in the U.S.

Total Glatiramer Acetate Weekly TRx Volume

Total GA Weekly TRx Volume



Global Copaxone Revenues by quarter




Source: Company information. Market share data is provided by IQVIA




AUSTEDO® continues to grow

AUSTEDO® Unique Patients Dispensed Per Quarter



Austedo® revenues by quarter



*Q1 unique patient dispensed count changed to 4,100 from 3,310 previously reported due to inclusion of IQVIA LRx data post open distribution model change

Source: Company information.

fremanezumab

- PDUFA action date for fremanezumab is set for September 16, 2018; we are preparing to launch the product immediately following approval
- FDA pre-approval inspection (PAI) completed in July 2018
- European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for fremanezumab; expect EMA action on the MAA in the first half of 2019

Strategy principles



One company



Organic growth



Leadership in Generics



Biologics as core R&D platform



Targeted investments

Generics – our way forward



Portfolio

- Proactive **portfolio selection** and management
- Keep focus on **first to market and high-barrier**
- Leverage and grow **TAPI and OTC** as core assets
- Increase success rate in approvals



Profitability

- **Improve pricing**, grow top and bottom line from existing products
- Benefit from restructuring through **higher productivity and efficiency** in global operations and elsewhere



Biosimilars

- **Build a Biosimilars pipeline** and manufacturing capabilities
- Develop internally and through selected partnering

Specialty – our way forward



Commercial

- Ensure the commercial success of core assets
- Continue to build our **commercial capabilities** in new franchises and geographies
- Prioritize **internal capabilities** to launch and commercialize over partnerships




R&D

- Build a Biologics platform: expand our in-house **Biologics** capabilities
- Focus the **inhaler technologies** on lifecycle management opportunities
- Advance to proof-of-concept the non-core programs
- Selective early stage in-licensing within CNS and Respiratory


Long term financial targets

To be achieved within 3-5 years


Operating Income Margin*¹



Cash-to-earning*²



Net debt/EBITDA*³



Committed to utilizing cash flow to pay down debt; we do not plan to raise equity

¹ Operating income margin = Non-GAAP operating income divided by net revenues

² Cash to earnings = Free cash flow divided by non-GAAP net income attributable to ordinary shareholders

³ Net debt/EBITDA = Net debt/ non-GAAP EBITDA

*All measures including operating income, EBITDA and earnings are presented on a non-GAAP basis

Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Progress made so far

- ✓ Restructuring program on schedule
- ✓ Net debt down to \$28.4 billion
- ✓ Revenue, FCF and EPS on track
- ✓ Copaxone[®] maintaining share in the U.S.
- ✓ Austedo[®] continues to grow
- ✓ Preparing for fremanezumab



Raised 2018 guidance
Non-GAAP EPS
Free Cash flow

Michael McClellan

Chief Financial Officer



Q2 2018 Summary

\$ millions, except EPS	Q2 2018	Q2 2017	Q2 2018	Q2 2017
	GAAP		Non-GAAP	
Revenues	4,701	5,720	4,701	5,720
Operating income (loss)	(14)	(5,740)	1,238	1,597
Net income (loss) attributable to Teva	(176)	(5,970)	859	1,100
Earnings (loss) per share (\$)	(0.24) 1,018M Shares	(5.94) 1,017M shares	0.78 1,021M shares	1.02 1,017M shares

Q2 2018 Non-GAAP Adjustments

\$ millions	Q2 2018	Highlights
Impairment	668	US intangible assets, Mexico reporting unit goodwill
Amortization	302	
Restructuring	107	
Equity compensation plans	47	
Legal Settlements	20	
Other items	94	Mainly Contingent consideration on Bendeka
Tax items effect	(203)	
Total adjustments	1,035	

Q2 2018 Non-GAAP Summary

\$ billions, except EPS	Q2 2018	Q2 2017	Change
Revenues	4.7	5.7	(18%)
Gross profit	2.4 50.4%	3.3 57.0%	(27%)
Operating income	1.2 26.3%	1.6 27.9%	(22%)
EBITDA	1.4	1.7	(20%)
Net income	0.8	1.1	(22%)
EPS (\$)	0.78 1,021M shares	1.02 1,017M shares	(24%)
Free cash flow*	0.6	0.6	(1%)
Total cash generated**	0.5	(0.1)	n/a


- * Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables
- ** Q2 2017 cash generated includes \$0.4b of dividend payments and \$0.3b acquisition of Takeda LLPs

Q2 2018 Foreign Exchange Impact

\$ millions	Q2 2018	Q2 2017	Diff	FX Effect	Diff net FX
Revenues	4,701	5,720	(1,019)	92	(1,111)
Operating income (loss) GAAP	(14)	(5,740)	5,726	14	5,712
Operating income Non-GAAP	1,238	1,597	(359)	19	(378)

Quarterly Revenues

\$ millions




* Segments and divestments data are net of the impact of foreign exchange fluctuations.

** Divestment & Other mainly includes Women's Health divestment, closure of Hungary distribution activities, deconsolidation of Venezuela, proceeds from the Ninlaro[®] transaction in 2017 and payment received from Otsuka in 2017

Copaxone[®] revenues and US market shares


\$ millions / % market share



Market share data is provided by IQVIA.

Quarterly Non-GAAP Operating Income


\$ millions



Profit is presented on a non-GAAP basis. Percentages may not add up to 100% due to rounding.

Spend Base: H1 2018 vs. H1 2017


\$ millions



- On track to achieve \$1.5B reduction in spend base in 2018
- FTE reduced by ~8,3K since the start of the restructuring plan

Free Cash Flow


\$ millions



- * Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Q2 2018 Net Debt Movement

\$ billions



* Net Debt = Gross Debt – cash balance

2018 Financial Outlook



2018 Non-GAAP Financial Outlook

	2018 Outlook – Original (Feb 2018)	May 2018 Outlook	August 2018 Outlook
Revenues (\$ billions)	18.3-18.8	18.5-19.0	18.5-19.0
Non-GAAP Operating income (\$ billions)	4.0-4.3	4.2-4.5	4.3-4.6
Non-GAAP EBITDA (\$ billions)	4.7-5.0	4.9-5.2	5.0-5.3
Non-GAAP EPS (\$)	2.25-2.50	2.40-2.65	2.55-2.80
Free cash flow (\$ billions)	2.6-2.8	3.0-3.2	3.2-3.4


Q&A



Additional Information

Quarterly EBITDA


\$ billions



EBITDA is based on non-GAAP operating income (which excludes amortization and certain other items) and excludes depreciation expenses

Quarterly Revenue Breakdown by Segment

\$ millions



Percentages may not add up to 100% due to rounding.

Revenues by Activity and Geographical Area

\$ millions	Q2-16	Q3-16	Q4-16	Q1-17	Q2-17	Q3-17	Q4-17	Q1-18	Q2-18
North America segment	2,724	2,901	3,473	3,240	3,169	3,043	2,689	2,531	2,263
Generic Medicines	931	1,316	1,429	1,415	1,331	1,233	1,224	1,088	947
Copaxone	968	892	846	797	859	819	641	476	464
Treanda and Bendeka	207	148	150	156	163	179	158	181	160
ProAir	135	118	139	121	123	155	102	130	115
QVAR	102	84	102	84	98	83	48	107	30
Austedo	0	0	0	0	1	6	17	30	44
Distribution	0	0	301	295	275	294	289	331	320
Other	380	342	506	373	319	274	209	188	183
Europe Segment	1,150	1,288	1,385	1,341	1,295	1,380	1,450	1,442	1,328
Generic Medicines	682	828	949	850	822	871	928	997	907
Copaxone	149	151	140	152	138	150	155	153	140
Respiratory products	59	57	64	84	84	90	110	113	106
Other	259	252	233	255	250	269	258	180	174
International Markets segment	919	1,055	1,277	718	885	882	910	750	789
Generic Medicines	698	832	1,047	486	604	629	651	488	537
Copaxone	24	19	29	21	26	18	26	16	22
Distribution	119	119	112	125	135	146	144	153	154
Other	78	85	89	86	120	89	90	93	76
Other Activities	246	319	356	351	371	312	349	342	321
API	208	191	181	197	204	171	181	179	186
Other (CMO)	38	129	175	154	167	141	168	163	135
Total Teva	5,038	5,563	6,492	5,650	5,720	5,617	5,398	5,065	4,701

Quarterly GAAP Income Statement

\$ millions, except EPS	Q2-18	Q2-18 Margins	Q2-17	Q2-17 Margins	Change
Revenues	4,701		5,720		(18%)
COGS	2,640	56.2%	2,865	50.1%	(8%)
Gross profit	2,061	43.8%	2,855	49.9%	(28%)
R&D	290	6.2%	469	8.2%	(38%)
S&M	710	15.1%	944	16.5%	(25%)
G&A	316	6.7%	363	6.3%	(13%)
Legal settlements and loss contingencies	20	0.4%	324	5.7%	(94%)
Impairments, restructuring and others	835	17.7%	6,519	113.9%	(87%)
Other income	(96)	(2.0%)	(24)	(0.4%)	+300%
Operating income	(14)	(0.3%)	(5,740)	(100.3%)	(100%)
Finance exp.	236	5.0%	238	4.2%	(1%)
Tax	(76)	30.4%	(22)	0.4%	+245%
Minority and share in profit (loss)	2	0.0%	14	0.2%	(86%)
Net income attributable to Teva	(176)	(3.7%)	(5,970)	(104.3%)	(97%)
Dividends on preferred shares	65		65		
Net income attributable to ordinary shareholders	(241)		(6,035)		
# of shares (diluted, millions)	1,018		1,017		
Earnings (loss) per share (\$)	(0.24)		(5.94)		(96%)

H1 2018 GAAP Income Statement

\$ millions, except EPS	H1-18	H1-18 Margins	H1-17	H1-17 Margins	Change
Revenues	9,766		11,370		(14%)
COGS	5,357	54.9%	5,676	49.9%	(6%)
Gross profit	4,409	45.1%	5,694	50.1%	(23%)
R&D	607	6.2%	901	7.9%	(33%)
S&M	1,481	15.2%	1,902	16.7%	(22%)
G&A	645	6.6%	729	6.4%	(12%)
Legal settlements and loss contingencies	(1,258)	(12.9%)	344	3.1%	n/a
Impairments, restructuring and others	1,722	17.6%	6,759	59.4%	(75%)
Other income	(299)	(3.1%)	(96)	(0.8%)	+211%
Operating income	1,511	15.5%	(4,845)	(42.6%)	n/a
Finance exp.	507	5.2%	445	3.9%	+14%
Tax	(30)	(3.0%)	32	(0.6%)	n/a
Minority and share in profit (loss)	90	0.9%	3	0.0%	n/a
Net income attributable to Teva	944	9.7%	(5,325)	(46.8%)	n/a
Dividends on preferred shares	130		130		
Net income attributable to ordinary shareholders	814		(5,455)		
# of shares (diluted, millions)	1,020		1,016		
Earnings (loss) per share (\$)	0.80		(5.37)		n/a

H1 2018 Non-GAAP Adjustments

\$ millions	H1 2018	Highlights
Impairment items	1,374	US intangible assets, Mexico reporting unit goodwill, termination of PGT Healthcare JV, production sites slated for closure
Amortization	612	
Restructuring	354	
Equity compensation	77	
Financial expenses	66	Early redemption fees
Contingent consideration	55	
Other items	105	
Capital gain	(83)	Women's health business divestment
Tax items effect	(368)	
Legal settlements	(1,258)	Actavis WC, Rimisa settlement, reversal of GSK anti-trust Carvedilol judgment
Total adjustments	934	


Consolidated Balance Sheet

\$ billions	June 30, 2018	Dec 31, 2017	Diff
Cash and Cash Equivalents	1.9	1.0	0.9
AR Trade	6.1	7.1	-1.1
Pre-paid Expenses and Other Current Assets	1.8	2.4	-0.5
Inventory	5.0	4.9	0.0
Fixed Assets	7.2	7.7	-0.5
Intangible Assets	16.2	17.6	-1.4
Goodwill	27.6	28.4	-0.8
Other Long Term Assets	1.2	1.5	-0.3
Total Assets	67.0	70.6	-3.6
AP Trade	1.8	2.1	-0.3
SR&A	7.1	7.9	-0.7
AP Other	4.0	4.3	-0.3
Total Debt (ST+LT)	30.2	32.5	-2.2
Other Long Term liabilities	4.5	5.1	-0.6
Minority	1.4	1.4	0.0
Teva Shareholders' Equity	17.9	17.4	0.6
Total Liabilities & Equity	67.0	70.6	-3.6

Some amounts may not sum due to rounding.

Liquidity


\$ billions



* According to Teva's credit agreement covenant ratio - adjusted ratio excludes EBITDA contribution of the divested WH business for the relevant test period; Teva's Net Debt/EBITDA covenants were amended to 5.50x, 5.75x, 5.90x and 5.90x for Q1-Q4 2018, respectively.

Q2-18 Cash Flow* Bridge


\$ millions



- *Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Updated Debt Maturities

\$ millions



In July 2018 Teva repaid \$300m in Swiss Franc at maturity